Regeneron Pharmaceuticals Inc (REGN) Financials
Key financial figures for Regeneron Pharmaceuticals Inc (Q3 2026).
Regeneron's Q3 2026 revenue rose 36% to $5.1 billion and non-GAAP EPS rose 70% to $20.07, as Sanofi collaboration revenue jumped 68% once the Development Balance was fully repaid. Total revenues were $5,115.8 million, up 36% from $3,754.3 million a year earlier. GAAP diluted EPS was $18.45 (up 35% from $13.62) and non-GAAP diluted EPS was $20.07 (up 70% from $11.83), both above the $16.51 EPS estimate on the SentiSense earnings calendar. Sanofi collaboration revenue rose 68% to $2,724.0 million. Regeneron's share of antibody profits was $2,574.9 million versus $1,455.5 million, and the release says the Sanofi Development Balance was fully repaid at the end of Q2 2026 and no longer reduced collaboration revenue from Q3. On the outlook: Full-year 2026 guidance updated in the release (no revenue or EPS guidance given): GAAP R&D $6.600-$6.735 billion (prior $6.500-$6.635 billion); non-GAAP R&D $6.050-$6.150 billion (prior $5.950-$6.050 billion); GAAP SG&A $2.730-$2.860 billion (prior $2.830-$2.960 billion); non-GAAP SG&A $2.400-$2.500 billion (prior $2.500-$2.600 billion); GAAP gross margin on net product sales approximately 80% (prior 78%-79%); non-GAAP gross margin approximately 86% (prior 84%-85%); capital expenditures $1.050-$1.100 billion (prior $1.030-$1.100 billion); GAAP effective tax rate approximately 14% (prior 13%-14%); non-GAAP effective tax rate approximately 15% (prior 14%-15%); GAAP and non-GAAP cost of collaboration and contract manufacturing unchanged. Figures are for Q3 2026, as Regeneron Pharmaceuticals, Inc. reported them.
- Revenue
- $5.1B
- Net Income
- $1.9B
- EPS
- $19.16
- Total Assets
- $44.4B
- Operating Cash Flow
- $1.8B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $5.1B | $1.9B | $18.45 | 40.04% | $1.5B |
| Q2 FY2026 | $4.3B | $1.3B | $12.23 | 33.11% | $334M |
| Q1 FY2026 | $3.6B | $727M | $6.75 | 17.83% | $848M |
| Q4 FY2025 | $3.9B | $845M | $7.86 | 22.65% | $922M |
| Q3 FY2025 | $3.8B | $1.5B | $13.62 | 27.35% | $1.4B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $14.3B | $4.5B | $41.48 | 24.95% | $4.1B |
| FY2024 | $14.2B | $4.4B | $38.34 | 28.1% | $3.7B |
| FY2023 | $13.1B | $4.0B | $34.77 | 33.15% | $3.7B |
Frequently asked questions
What was Regeneron Pharmaceuticals, Inc.'s revenue last quarter?
Regeneron Pharmaceuticals, Inc. reported revenue of $5.12 billion for Q3 FY2026, up 36.3% from the same period a year earlier.
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. Regeneron Pharmaceuticals, Inc. reported net income of $1.95 billion for Q3 FY2026, a net margin of 38.09% on revenue.
How has Regeneron Pharmaceuticals, Inc.'s margin trended?
Operating margin was 40.04% in Q3 FY2026, compared with 27.35% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Regeneron Pharmaceuticals, Inc. generate?
Regeneron Pharmaceuticals, Inc. generated free cash flow of $1.48 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Regeneron Pharmaceuticals Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.